Collegium Pharmaceutical Inc(COLL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 7:10 AM ET (Korea 10/28 20:10)
Full metrics table
| Index | RUT | P/E | 18.63 | EPS (ttm) | 1.23 | Insider Own | 1.85% | Shs Outstand | 32.5M | Perf Week | -0.99% |
| Market Cap | 0.75B | Forward P/E | 3.17 | EPS next Y | -2.68% | Insider Trans | -2.8% | Shs Float | 31.9M | Perf Month | 1.64% |
| Enterprise Value | 1.82B | PEG | 2.53 | EPS next Q | 1.86 | Inst Own | 126.52% | Short Float | 16.82% | Perf Quarter | -36.62% |
| Income | 0.05B | P/S | 0.93 | EPS this Y | 0.52% | Inst Trans | 1.21% | Short Ratio | 6.72 | Perf Half Y | -29.9% |
| Sales | 0.81B | P/B | 2.4 | EPS next 5Y | 1.25% | ROA | 2.57% | Short Interest | 5.38M | Perf YTD | -50.32% |
| Book/sh | 9.6 | P/C | 5.01 | EPS past 3/5Y | - 17.92% | ROE | 17.61% | 52W High | -54.71% ($50.79) | Perf Year | -33.94% |
| Cash/sh | 4.59 | P/FCF | 2.28 | Sales past 3/5Y | 18.94% 20.28% | ROIC | 3.25% | 52W Low | 7.33% ($21.43) | Perf 3Y | 8.7% |
| Dividend Est. | - | EV/EBITDA | 4.59 | EPS Y/Y TTM | 34.35% | Gross Margin | 60.02% | Volatility(W/M) | 3.51% 3.37% | Perf 5Y | 11.06% |
| Dividend TTM | - | EV/Sales | 2.25 | Sales Y/Y TTM | 14.31% | Oper. Margin | 20.12% | ATR (14) | 0.85 | Perf 10Y | 53.74% |
| Dividend Ex-Date | - | Quick Ratio | 0.84 | EPS Q/Q | -234.56% | Profit Margin | 5.93% | RSI (14) | 49.37 | Recom | 1.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.03 | Sales Q/Q | 6.32% | SMA20 | 2.26% ($22.49) | Beta | 0.76 | Target Price | $49 |
| Payout | - | Debt/Eq | 3.9 | Earnings | 2026/11/5 | SMA50 | -2.43% ($23.57) | Rel Volume | 0.61 | Prev Close | $23.21 |
| Employees | 423 | LT Debt/Eq | 3.72 | EPS/Sales Surpr. | 11.69% 0.13% | SMA200 | -31.53% ($33.59) | Avg Volume(3M) | 0.80M | Price | $23 |
| IPO | 2015/5/7 | Option/Short | Yes/Yes | Trades | 7497 | Volume | 486,634 | Change | -0.9% |
💊 Collegium Pharmaceutical (COLL) is a diversified specialty pharmaceutical company focused on pain management. It holds Xtampza extended-release tablets, built on its abuse-deterrent DETERx technology platform, and the Nucynta franchise as core assets, and has recently expanded its portfolio by adding assets in the attention-deficit/hyperactivity disorder (ADHD) space. The company is dedicated to prescription medications for patients with serious conditions, including chronic pain.
Over the past 1 year, on the lower side
55% below its 1-year high.
Traded less than usual. That is 61% of its average volume.
Next earnings report: November 5
8 days to go.
COLL makes money exceptionally well
Of every $100 in sales, $20.12 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +0.5% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $459. Peers typically go for $1,429. It is about in line with its own 4-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be +11.1%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 126.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #35 of 83 in the industry
Based on market cap of $749M.
HROW#33 Harrow Inc $1B PER - 
AMPH#34 Amphastar Pharmaceuticals Inc $1B PER 15.0 COLL#35 Collegium Pharmaceutical Inc $749M PER 18.6 
IRWD#36 Ironwood Pharmaceuticals Inc $580M PER 4.6 
EVO#37 Evotec SE ADR $558M PER - 
FAQ
What kind of company is COLL?
COLL belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of COLL?
The market cap of COLL is approximately $749M, ranking 2,810 within its sector.
What is the P/E ratio of COLL?
COLL has a P/E ratio of approximately 18.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for COLL?
COLL has recorded a 52-week high of $50.79 and a low of $21.43.
